766 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
ABBV AbbVie Inc. $95.37 $144.42B N/A
Article Searches
Novartis Reports Additional Data on Spondylitis Drug Cosentyx http://www.zacks.com/stock/news/547460/novartis-reports-additional-data-on-spondylitis-drug-cosentyx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-547460 Oct 03, 2019 - Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.
Top Ranked Income Stocks to Buy for October 2nd http://www.zacks.com/commentary/545738/top-ranked-income-stocks-to-buy-for-october-2nd?cid=CS-ZC-FT-zacks_#1_rank_additions-545738 Oct 02, 2019 - Top Ranked Income Stocks to Buy for October 2nd
3 Stocks With Dividends Over 5% That Are Great for Income Investors https://www.fool.com/investing/2019/10/02/3-stocks-with-dividends-over-5-that-are-great-for.aspx?source=iedfolrf0000001 Oct 02, 2019 - These dividend stocks pay high yields and can be a great way to add cash flow to your portfolio.
Top Stock Reports for AbbVie, Starbucks & Phillips 66 http://www.zacks.com/research-daily/544529/top-stock-reports-for-abbvie-starbucks-phillips-66?cid=CS-ZC-FT-research_daily-544529 Oct 01, 2019 - Top Stock Reports for AbbVie, Starbucks & Phillips 66
Here is Why Growth Investors Should Buy AbbVie (ABBV) Now http://www.zacks.com/stock/news/542551/here-is-why-growth-investors-should-buy-abbvie-abbv-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_11_growth-542551 Sep 30, 2019 - AbbVie (ABBV) could produce exceptional returns because of its solid growth attributes.
3 Dividend Stocks That Are Perfect for Retirement https://www.fool.com/investing/2019/09/30/3-dividend-stocks-that-are-perfect-for-retirement.aspx?source=iedfolrf0000001 Sep 30, 2019 - These three businesses provide current income while protecting a portfolio from inflation.
AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug http://www.zacks.com/stock/news/539107/abbvie-abbv-gets-fda-nod-for-label-expansion-of-hcv-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-539107 Sep 27, 2019 - AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.
AC Immune to Earn Milestone From Lilly for Alzheimer's Drug http://www.zacks.com/stock/news/532222/ac-immune-to-earn-milestone-from-lilly-for-alzheimers-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-532222 Sep 23, 2019 - AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
Top Analyst Reports for AbbVie, Union Pacific & CSX http://www.zacks.com/research-daily/524511/top-analyst-reports-for-abbvie-union-pacific-csx?cid=CS-ZC-FT-research_daily-524511 Sep 18, 2019 - Top Analyst Reports for AbbVie, Union Pacific & CSX
Novartis Announces New Data on Spondylitis Drug Cosentyx http://www.zacks.com/stock/news/522872/novartis-announces-new-data-on-spondylitis-drug-cosentyx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-522872 Sep 17, 2019 - Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.

Pages: 12345678910...77

<<<Page 5>